The Stem Cell Podcast: Ep 228 – “Developing Regenerative Medicines” Featuring Dr. Stefan Irion

Dr. Stefan Irion is the Senior Vice President of Research at BlueRock Therapeutics, a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. He talks about the company’s Parkinson’s disease trial and the challenges of genetically manipulating stem cells. He also discusses his journey from physician to scientist and his personal connection to Parkinson’s disease.

Click Here To Listen

Related News

Press Releases

BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan

December 17, 2025
Press Releases

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

October 7, 2025
Press Releases

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel 

September 22, 2025
Press Releases

BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan

December 17, 2025
Press Releases

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

October 7, 2025
Press Releases

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel 

September 22, 2025